Insights - Endo Health (ENDP) and Auxilium Pharmaceuticals (AUXL) finally came to terms in ongoing buyout negotiations, with ENDP handing over $2.6 billion ($33.25 per share) in … Continue Reading
Read nowRecap - Auxilium Pharmaceuticals (AUXL) was approached by Endo Pharmaceuticals (ENDP) this week in a $2.2 billion unsolicited acquisition attempt. The stock and cash deal would represent … Continue Reading
Read nowInsights - Auxilium's (AUXL) Xiaflex improves cellulite appearance in a phase 2a, 150-women study.
Read nowRecap - The announcement came two weeks ahead of schedule, and Afrezza is now approved to improve glycemic control in adults with diabetes mellitus. Afrezza’s label includes a Black Box Warning … Continue Reading
Read nowInsights - Driven by Canada’s lower corporate tax rate, Auxilium Pharmaceuticals (AUXL) plans to merge with QLT Inc. (QLTI), a small Canadian biotechnology company that essentially put … Continue Reading
Read nowRecap - Sarepta Therapeutics (SRPT) on Thursday morning released its fourth quarter and full-year 2013 financial results. The company continues to await guidance from the FDA on the … Continue Reading
Read nowInsights - QLT Inc (QLTI) reported positive retreatment data on Thursday for its synthetic oral retinoid compound QLT091001 (-001), indicated for the orphan designated Leber Congenital Amaurosis … Continue Reading
Read now
